Spotlight – KRS: A cut away from release in exosomes

JCB

KRS: A cut away from release in exosomes

 
Catherine Rabouille

Cancer cells often trigger an inflammatory process, which in some cases may be driven by the presence of lysyl-tRNA synthetase (KRS) in the medium. Kim et al. (2017. J. Cell Biol.https://doi.org/10.1083/jcb.201605118) now demonstrate that cleavage of the KRS by caspase-8 inside cells triggers its interaction with syntenin and its release in inflammatory exosomes.

Aminoacyl-tRNA synthetases (ARSs) are intriguing enzymes. Intracellularly, they catalyze the covalent attachment of amino acids to tRNAs and are key regulators of protein translation. However, these housekeeping enzymes have many other tricks up their sleeves. In the cell, several ARSs are also able to regulate gene expression at the level of transcription, splicing, and translation but via noncatalytic and unique mechanisms. ARSs also have different functions in the extracellular space, where they can elicit cytokine signaling responses that control angiogenesis, induce immune and proinflammatory gene expression programs, and trigger cell migration or apoptosis. The response elicited by particular ARSs is specific to the target cells (Son et al., 2014). For instance, when present in the extracellular medium, lysyl-tRNA synthetase (KRS) binds to macrophages and monocytes and activates MAPK signaling pathways that induce macrophage migration and TNF production (Park et al., 2005). How ARSs are released to the extracellular medium to carry out these activities is unknown. ARSs do not contain a signal peptide, and pharmacological agents blocking secretion through the secretory pathway have no effect on the amount of ARS in the medium. For a while, the presence of ARSs in the extracellular medium was thus thought to be caused by their passive release from cells that have undergone necrosis. In this issue, Kim et al. reinvestigate how KRS is released from cancer cells and find that this occurs through a caspase-8– and syntenin-dependent incorporation of KRS in exosomes.

http://jcb.rupress.org/content/early/2017/06/15/jcb.201706039

Related Post

전염병 치료 타겟으로의 ARS, Biochemical Pharmacology Mini Re...
views 756
  Biocon 세부 과제 책임자이신 한국생명공학연구원 김명희 박사님(사진 왼쪽)과 김성훈 단장님이 작업한 Mini Review 논문이 Biochemical Pharmacology에 발표 되었습니다. 논문 제목은 "Aminoacyl-tRNA ...
백신 개발·DNA 해독… 전염병 막을 ‘국제연합군’ 뭉쳤다...
views 672
백신 개발·DNA 해독… 전염병 막을 '국제연합군' 뭉쳤다 박건형 기자 황승식 서울대 보건대학원 교수 입력 : 2017.06.03 03:02 판데믹에 맞서는 인류 WHO·美·유럽 중심으로 에볼라 백신 개발 성공 빌 게이...
A paper on a new ARS receptor was published in the...
views 597
Dr. Hyuck Sang Kwon's article was published in the Journal of Cell Science for discovering  a new AIMP1 receptor.   The title of the article...
IDA: Integrated Database for Aminoacyl-tRNA Synthe...
views 1045
We would like to annouce that an integrated database for aminoacyl-tRNA synthetases are now open to public, presented by SNU Biocon and Postech Syst...

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2010-2019 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?

Skip to toolbar